Asset profile
alvelestat
Small molecule
Evidence outlook · lead readout
NCT03636347 · Alpha 1-Antitrypsin Deficiency, Emphysema, COPD
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT03636347: The trial randomized 99 participants to two alvelestat dose groups or placebo and used quadruple blinding. Its primary endpoints were blood biomarkers rather than clinical or endoscopic outcomes, and no primary-endpoint results are available, so the treatment effect remains unknown.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.